Course Summary
Contact Hour(s):
2 Contact Hours, including 2 Advanced Pharmacology Hours
Author:
Julia Tortorice, RN, MBA, MSN, NEA-BC, CPHQ
This peer-reviewed course is applicable for the following professions:
Advanced Practice Registered Nurse (APRN), Certified Nurse Practitioner, Certified Registered Nurse Anesthetist (CRNA), Certified Registered Nurse Practitioner, Clinical Nurse Specialist (CNS), Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Nursing Student, Registered Nurse (RN), Registered Nurse Practitioner
Accreditations:
The American Nurses Credentialing Center (ANCC)
State Approvals:
Alabama, Provider #ABNP1485; California BRN Provider #CEP # 13509; Kentucky Board of Nursing Provider #7-0085; Florida Board of Nursing Provider 50-353;
Course Description:
This course discusses best practices for prescribing controlled substances, including the Centers for Disease Control and Prevention's (CDC) Clinical Practice Guidelines and recommendations.
Outcomes:
≥ 92% of participants will understand the Centers for Disease Control and Prevention's (CDC) 2022 Clinical Practice Guidelines for Opioids and Iowa laws regarding controlled substance prescribing and monitoring.
Objectives:
After completing this continuing education course, the participant will be able to:
After completing this continuing education course, the participant will be able to:
- Explain the Centers for Disease Control and Prevention's (CDC's) guidelines for prescribing opiates.
- Summarize the accepted best practices for assessing patients' risk for addiction and misuse of controlled substances.
- Compare treatment for specific pain types.
- Identify tools for identifying the risk of diversion, addiction, and misuse.
- Describe the treatment of patients with acute, sub-acute, and chronic pain for whom nonpharmacological and noncontrolled pain medications have not been fully effective.
- Identify three ways that controlled substances can be diverted.
Disclosures:
CEUFast Inc. and the course planning team for this educational activity do not have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
